Team:Stony Brook

From 2014.igem.org

(Difference between revisions)
 
(38 intermediate revisions not shown)
Line 5: Line 5:
<style type="text/css">
<style type="text/css">
 +
 +
#contentSub, #footer-box, #catlinks, #search-controls, #p-logo, .printfooter, .firstHeading,.visualClear {display: none;}
 +
body {
body {
background-image: url(https://static.igem.org/mediawiki/2014/a/a5/Stony_brook_home_background.png);
background-image: url(https://static.igem.org/mediawiki/2014/a/a5/Stony_brook_home_background.png);
Line 25: Line 28:
#navigation {
#navigation {
-
width: 65px;
+
width: 90px;
padding: 9px;
padding: 9px;
float: left;
float: left;
Line 37: Line 40:
#navigation p{
#navigation p{
display:none;
display:none;
 +
        text-align:center;
}
}
Line 55: Line 59:
#navigation_container {
#navigation_container {
-
width: 520 px;
+
width: 1000 px;
-
position: absolute;
+
position: absolute;
-
top: 40%;
+
top: 37%;
-
right: 50%;
+
right: 50%;
-
margin-right: -263px;
+
margin-right: -450px;
-
margin-top:-50px;
+
}
}
 +
Line 105: Line 109:
#login a:hover{
#login a:hover{
color: #0F0;
color: #0F0;
 +
}
 +
 +
.firstHeading {
 +
      visibility: hidden;
}
}
Line 126: Line 134:
left:50%;
left:50%;
width:584px;
width:584px;
-
height:340px;
+
height:320px;
margin-left:-265.6px;
margin-left:-265.6px;
-
margin-bottom:-127px;
+
margin-bottom:-107px;
overflow:auto;
overflow:auto;
Line 152: Line 160:
left:50%;
left:50%;
width:584px;
width:584px;
-
height:340px;
+
height:320px;
background-color:#000;
background-color:#000;
margin-left:-265.6px;
margin-left:-265.6px;
-
margin-bottom:-127px;
+
margin-bottom:-107px;
color: #FFF;
color: #FFF;
-
background-opacity:0.5;
+
opacity:0.6;
-
filter: alpha(opacity=50);
+
filter:alpha(opacity=60);
 +
}
</style>
</style>
Line 168: Line 177:
<a href="https://igem.org/Main_Page"><img src="https://static.igem.org/mediawiki/2014/5/51/Stony_brook_igem_logo.png" alt= "iGEM logo" name="iGEM_logo" border="0px" id="iGEM_logo" /></a>
<a href="https://igem.org/Main_Page"><img src="https://static.igem.org/mediawiki/2014/5/51/Stony_brook_igem_logo.png" alt= "iGEM logo" name="iGEM_logo" border="0px" id="iGEM_logo" /></a>
-
<a href="https://www.facebook.com/iGEMatstonybrook"><img src="https://static.igem.org/mediawiki/2014/0/0f/Stony_brook_fb_logo.png" alt= "facebook" name="facebook" border="0px" id="facebook" /></a></a>
+
<a href="http://www.facebook.com/iGEMatstonybrook"><img src="https://static.igem.org/mediawiki/2014/0/0f/Stony_brook_fb_logo.png" alt= "facebook" name="facebook" border="0px" id="facebook" /></a></a>
-
<a href="https://twitter.com/iGEMSBU"><img src="https://static.igem.org/mediawiki/2014/b/b5/Stony_brook_twitter_logo.png" alt= "twitter" name="twitter" border="0px" id="twitter" /></a></a>
+
<a href="http://twitter.com/iGEMSBU"><img src="https://static.igem.org/mediawiki/2014/b/b5/Stony_brook_twitter_logo.png" alt= "twitter" name="twitter" border="0px" id="twitter" /></a></a>
<div id="header"><a href="https://2014.igem.org/Team:Stony_Brook"><img src="https://static.igem.org/mediawiki/2014/1/11/Stony_brook_header.png" alt="Stony Brook iGEM" border="0px"" /></a></div>
<div id="header"><a href="https://2014.igem.org/Team:Stony_Brook"><img src="https://static.igem.org/mediawiki/2014/1/11/Stony_brook_header.png" alt="Stony Brook iGEM" border="0px"" /></a></div>
-
<!-- <div id="navigation_container">
+
<div id="navigation_container">
     <div id="navigation"> <a href="https://2014.igem.org/Team:Stony_Brook"><img src="https://static.igem.org/mediawiki/2014/b/b8/Stony_Brook_NavIcon.Home.png"  border="0px" /></a>
     <div id="navigation"> <a href="https://2014.igem.org/Team:Stony_Brook"><img src="https://static.igem.org/mediawiki/2014/b/b8/Stony_Brook_NavIcon.Home.png"  border="0px" /></a>
Line 194: Line 203:
<p>Notebook</p>
<p>Notebook</p>
     </div>
     </div>
-
 
+
<div id="navigation">
 +
  <a href="https://2014.igem.org/Team:Stony_Brook/Results"> <img src="https://static.igem.org/mediawiki/2014/c/c3/Stony_Brook_NavIcon.Results.png"/></a>
 +
      <p>Results</p>
 +
</div>
<div id="navigation">
<div id="navigation">
-
  <a href="http://www.igem.org"> <img src="https://static.igem.org/mediawiki/2014/e/e2/Stony_Brook_Navicon.Outreach.png" border="0px"/></a>
+
  <a href="https://2014.igem.org/Team:Stony_Brook/Outreach"> <img src="https://static.igem.org/mediawiki/2014/e/e2/Stony_Brook_Navicon.Outreach.png" border="0px"/></a>
<p>Outreach</p>
<p>Outreach</p>
     </div>  
     </div>  
 +
<div id="navigation">
 +
  <a href="https://2014.igem.org/Team:Stony_Brook/Safety"> <img src="https://static.igem.org/mediawiki/2014/8/81/Stony_Brook_NavIcon.Safety.png"/></a>
 +
      <p>Safety</p>
 +
</div>
     <div id="navigation">
     <div id="navigation">
-
  <a href="http://www.igem.org"> <img src="https://static.igem.org/mediawiki/2014/5/5e/Stony_Brook_NavIcon.Acknowledgements.png" border="0px"/></a>
+
  <a href="https://2014.igem.org/Team:Stony_Brook/Attributions"> <img src="https://static.igem.org/mediawiki/2014/5/5e/Stony_Brook_NavIcon.Acknowledgements.png" border="0px"/></a>
       <p>Attributions</p>
       <p>Attributions</p>
</div>  
</div>  
-
</div> -->
 
-
 
-
<div id="login">
 
-
<ul>
 
-
  <li><a href="https://2014.igem.org/Team:Stony_Brook">page</a></li>
 
-
  <li><a href="https://2014.igem.org/Talk:Team:Stony_Brook">discussion</a></li>
 
-
  <li><a href="https://2014.igem.org/wiki/index.php?title=Team:Stony_Brook&amp;action=edit">view source</a></li>
 
-
  <li><a href="https://2014.igem.org/wiki/index.php?title=Team:Stony_Brook&amp;action=history">history</a></li>
 
-
</ul>
 
</div>
</div>
-
<div id="background">
 
-
</div>
 
-
<div id="projectDescription">
+
<!-- <div id="background">
 +
</div> -->
 +
 
 +
<!-- <div id="projectDescription">
<h1> Project Description </h1>
<h1> Project Description </h1>
<p> The threat of antibiotic resistance has been a concern since the discovery of penicillin.  As antibiotics continue to be used to treat disease, pathogenic bacteria continue to develop resistance, eventually becoming irresponsive to multiple classes of antibiotics. This is a major problem for areas that must maintain sterile environments, such as hospitals or other health-care settings. Hospital-acquired infections (HAI) are already an existing issue that poses risks to people receiving or recovering from treatment. Gram-negative bacteria in particular are known to cause more HAIs as they are more resistant to antibiotics than gram-positive bacteria. Irresponsible use of antibiotics has only exacerbated this issue. Recent reports from the World Health Organization confirm that antibiotic resistance is no longer something to worry about in the future, but a current, global health threat. </p>
<p> The threat of antibiotic resistance has been a concern since the discovery of penicillin.  As antibiotics continue to be used to treat disease, pathogenic bacteria continue to develop resistance, eventually becoming irresponsive to multiple classes of antibiotics. This is a major problem for areas that must maintain sterile environments, such as hospitals or other health-care settings. Hospital-acquired infections (HAI) are already an existing issue that poses risks to people receiving or recovering from treatment. Gram-negative bacteria in particular are known to cause more HAIs as they are more resistant to antibiotics than gram-positive bacteria. Irresponsible use of antibiotics has only exacerbated this issue. Recent reports from the World Health Organization confirm that antibiotic resistance is no longer something to worry about in the future, but a current, global health threat. </p>
Line 224: Line 232:
<p> Our project this summer is to transform E. coli with the melittin gene in honey bees, so that the E. coli may express the melittin peptide, thereby developing a means to mass-produce melittin as an alternative to today's antibiotics. We hope to optimize the production of melittin in E. coli, as well as to test the bioactivity of our produced melittin in comparison to its naturally-occurring counterpart. </p>
<p> Our project this summer is to transform E. coli with the melittin gene in honey bees, so that the E. coli may express the melittin peptide, thereby developing a means to mass-produce melittin as an alternative to today's antibiotics. We hope to optimize the production of melittin in E. coli, as well as to test the bioactivity of our produced melittin in comparison to its naturally-occurring counterpart. </p>
-
</div>
+
</div> -->
</body>
</body>
</html>
</html>

Latest revision as of 03:44, 18 October 2014

facebook twitter